Infusion-related reactions during Natalizumab treatment: do we still need a post-infusion observation period?

ConclusionIn our cohort, NTZ associated IRR mainly occurred during the infusion period compared to the one-hour observational period. Also, the first IRR exclusively occurred within the first 4 NTZ administrations. However, further multi-center studies with a larger sample size are needed to capture rare and serious events that could emerge during the observational period and to make clinical recommendations.
Source: Multiple Sclerosis and Related Disorders - Category: Neurology Source Type: research

Related Links:

 Have you ever wondered what it’s like to be an inpatient in a psych ward? In this two-part series, we go into detail about Gabe’s inpatient stay starting with the events that lead him to be an inpatient, and what his days were like after he was admitted. We talk about common misconceptions that you may have around what happens while you’re admitted, what your day looks like and who you’d spend time with. (Transcript Available Below) SUBSCRIBE &REVIEW About The Not Crazy Podcast Hosts Gabe Howard is an award-winning writer and speaker who lives with bipolar disorder. He is the author of t...
Source: World of Psychology - Category: Psychiatry & Psychology Authors: Tags: Bipolar Depression General Not Crazy Podcast Psychiatry Psychotherapy Suicide Treatment Source Type: blogs
Conclusions The long-term risks of autoimmune disorders are significantly higher in patients with allergic diseases. Allergic diseases and autoimmune disorders show age- and sex-related clustering patterns.
Source: European Respiratory Journal - Category: Respiratory Medicine Authors: Tags: Asthma and allergy Original Articles: Asthma and allergy Source Type: research
A benign course of multiple sclerosis is rare, but a 5-year study shows younger patient age, earlier disease onset, female gender, and other factors may predict which MS cases will be benign.Medscape Medical News
Source: Medscape Allergy Headlines - Category: Allergy & Immunology Tags: Neurology & Neurosurgery News Source Type: news
What can we expect from the flu season this year? Unfortunately, many experts are predicting an active, and possibly severe, flu season. This projection is based on data from Australia, where the flu season is just wrapping up. Australia was hit early and hard by flu this year: over 300,000 patients had laboratory-confirmed influenza, a record number of cases. Flu outbreaks in the Southern Hemisphere happen during our summers, and they often give us a clue as to what we should expect when the flu lands on our shores in the fall. Who should get the flu vaccine? Basically, everybody over the age of 6 months, except for those...
Source: Harvard Health Blog - Category: Consumer Health News Authors: Tags: Cold and Flu Health Prevention Vaccines Source Type: blogs
The U.S. Food and Drug Administration on Wednesday approved Biogen Inc's new oral drug to treat multiple sclerosis, offering the drugmaker some relief as its core franchise faces patent challenges.Reuters Health Information
Source: Medscape Allergy Headlines - Category: Allergy & Immunology Tags: Neurology & Neurosurgery News Source Type: news
We present a patient where interferon-beta1a (IFN β1a) appears to amplify adverse effects of venom immunotherapy (VIT) and diminish desensitization. IFNβ1a is a disease modifying therapy for relapsing/remitting multiple sclerosis (MS). Her case is further complicated by her high sting risk occupation and living in a rural setting requiring helico pter transport for medical care.
Source: Annals of Allergy, Asthma and Immunology - Category: Allergy & Immunology Authors: Source Type: research
We describe successful desensitization of two patients with immediate hypersensitivity reactions to Ocrelizumab.
Source: Annals of Allergy, Asthma and Immunology - Category: Allergy & Immunology Authors: Source Type: research
Diroximel fumarate showed better GI tolerability compared with dimethyl fumarate in patients with relapsing forms of multiple sclerosis in the EVOLVE-MS-2 phase 3 study.FDA Approvals
Source: Medscape Allergy Headlines - Category: Allergy & Immunology Tags: Neurology & Neurosurgery News Alert Source Type: news
The promise of serum neurofilament light chain to diagnose multiple sclerosis continues to evolve, with new evidence supporting a role in identifying presymptomatic disease.Medscape Medical News
Source: Medscape Allergy Headlines - Category: Allergy & Immunology Tags: Neurology & Neurosurgery News Source Type: news
A new B cell-depleting therapy, given as a monthly subcutaneous injection, has shown impressive results in two phase 3 studies in relapse-remitting multiple sclerosis.Medscape Medical News
Source: Medscape Allergy Headlines - Category: Allergy & Immunology Tags: Neurology & Neurosurgery News Source Type: news
More News: Allergy | Allergy & Immunology | Italy Health | Multiple Sclerosis | Neurology | Study | Switzerland Health | Tysabri